2/22/2024 | IG | New Issue: AstraZeneca prices $5 billion guaranteed notes over four parts
|
2/21/2024 | IG | AstraZeneca Finance plans to price fixed-rate notes in four parts
|
8/10/2023 | IG | Moody’s boosts AstraZeneca
|
3/1/2023 | IG | New Issue: AstraZeneca sells $2.25 billion of five-, seven-, 10-year notes
|
2/28/2023 | IG | AstraZeneca prepares to sell five-, seven-, 10-year notes
|
11/28/2022 | IG | S&P raises AstraZeneca
|
11/17/2022 | IG | Fitch raises AstraZeneca
|
11/16/2022 | IG | Moody's alters AstraZeneca trend to stable
|
4/29/2022 | SP | New Issue: GS Finance sells $9.25 million basket-linked notes tied to 77 stocks
|
12/14/2021 | SP | New Issue: JPMorgan sells $1.22 million trigger autocallable contingent yield notes on AstraZeneca
|
12/13/2021 | IG | Fitch moves AstraZeneca view to positive
|
11/22/2021 | SP | New Issue: Citi prices $1.47 million autocallable contingent coupon equity notes on three stocks
|
8/26/2021 | SP | New Issue: GS Finance prices $13.14 million leveraged basket-linked notes on 179 stocks
|
7/21/2021 | IG | S&P raises AstraZeneca
|
5/26/2021 | IG | New Issue: AstraZeneca details $7 billion of notes in six parts
|
5/25/2021 | IG | New Issue: AstraZeneca sells $7.25 billion of notes in six parts
|
5/25/2021 | IG | AstraZeneca sets price talk for $8 billion of notes in seven parts
|
5/24/2021 | IG | AstraZeneca intends to price seven tranches of notes
|
2/9/2021 | SP | New Issue: Credit Suisse sells $1.4 million contingent coupon autocallables on pharma stocks
|
12/31/2020 | SP | New Issue: Credit Suisse sells $12.23 million contingent income autocalls on two pharma stocks
|
12/16/2020 | IG | S&P puts AstraZeneca on positive watch
|
12/15/2020 | IG | Fitch revises AstraZeneca view to stable
|
11/12/2020 | SP | New Issue: RBC prices $409,000 trigger autocallable contingent yield notes on AstraZeneca
|
11/12/2020 | IG | S&P shifts AstraZeneca view to positive
|
10/6/2020 | IG | Fitch alters AstraZeneca view to positive
|
9/18/2020 | SP | New Issue: Citi sells $1.7 million callable contingent coupon notes on three stocks
|
8/7/2020 | SP | New Issue: Citigroup sells $10 million equity-linked securities on three stocks
|
8/4/2020 | IG | New Issue: AstraZeneca gives details on $3 billion three-part sale of fixed-rate notes
|
8/3/2020 | EMHYPFPV | Market Commentary: Alphabet notes attract strong demand; AstraZeneca, Praxair, JetBlue, Textron, Kilroy price
|
8/3/2020 | IG | Market Commentary: Alphabet notes attract strong demand; AstraZeneca, Praxair, JetBlue, Textron, Kilroy price
|
8/3/2020 | IG | New Issue: AstraZeneca prices $3 billion of fixed-rate notes in three tranches
|
8/3/2020 | IG | Market Commentary: Morning Commentary: High-grade supply ramps up; Alphabet, AstraZeneca, Praxair, DTE eyed
|
8/3/2020 | IG | AstraZeneca to issue fixed-rate notes due 2026, 2030 and 2050
|
10/9/2019 | IG | Fitch affirms AstraZeneca
|
5/28/2019 | SP | Credit Suisse to price buffered return equity notes on stock basket
|
5/6/2019 | SP | Credit Suisse to price buffered return equity notes on stock basket
|
4/2/2019 | IG | Moody's lifts AstraZeneca view to stable
|
12/13/2018 | EMHYPFPV | Market Commentary: UnitedHealth sells $2.95 billion of notes; credit spreads firm; high-grade outflows rise
|
12/13/2018 | IG | Market Commentary: UnitedHealth sells $2.95 billion of notes; credit spreads firm; high-grade outflows rise
|
10/12/2018 | IG | Fitch trims AstraZeneca
|
8/27/2018 | EMHYPFPV | Market Commentary: Caterpillar reopens floaters; high-grade supply thins in front of holiday; bonds mixed
|
8/27/2018 | IG | Market Commentary: Caterpillar reopens floaters; high-grade supply thins in front of holiday; bonds mixed
|
8/27/2018 | IG | Market Commentary: Morning Commentary: High-grade market action thins in front of holiday; primary quiet
|
8/22/2018 | EMHYPFPV | Market Commentary: Supply picks up; Bank of America, Nordea, Zions, Timken price notes; AstraZeneca steady
|
8/22/2018 | IG | Market Commentary: Supply picks up; Bank of America, Nordea, Zions, Timken price notes; AstraZeneca steady
|
8/22/2018 | IG | Market Commentary: Morning Commentary: Timken to tap primary market; deal volume slows; AstraZeneca busy
|
8/17/2018 | EMHYPFPV | Market Commentary: High-grade volume subsides after solid week; United Technologies firms; McDonald’s mixed
|
8/17/2018 | IG | Market Commentary: High-grade volume subsides after solid week; United Technologies firms; McDonald’s mixed
|
8/17/2018 | IG | Market Commentary: Morning Commentary: Primary quiet after strong week; high-grade inflows mostly decline
|
8/16/2018 | EMHYPFPV | Market Commentary: AT&T, Huntington Bank, Protective Life, Willis Lease tap primary; AstraZeneca notes improve
|
8/16/2018 | IG | Market Commentary: AT&T, Huntington Bank, Protective Life, Willis Lease tap primary; AstraZeneca notes improve
|
8/15/2018 | IG | Market Commentary: Morning Commentary: Supply slows; South Carolina Electric offers bonds; Fluor eyed
|
8/15/2018 | IG | New Issue: AstraZeneca details $3 billion four-part fixed-, floating-rate notes
|
8/14/2018 | EMHYPFPV | Market Commentary: AstraZeneca, Elanco, Roper, Apache, AerCap price; United Technologies firms
|
8/14/2018 | IG | Market Commentary: AstraZeneca, Elanco, Roper, Apache, AerCap price; United Technologies, McDonald’s firm
|
8/14/2018 | IG | New Issue: AstraZeneca prices $3 billion of fixed- and floating-rate notes
|
8/14/2018 | IG | Market Commentary: Morning Commentary: Strong supply on tap; AstraZeneca, Apache, Roper, IBRD eye deals
|
8/14/2018 | IG | AstraZeneca to issue fixed-rate, floating-rate notes in four parts
|
8/1/2017 | IG | Fitch downgrades AstraZeneca to A-
|
7/28/2017 | IG | Moody’s changes AstraZeneca to negative
|
7/28/2017 | IG | S&P downgrades AstraZeneca, debt to BBB+
|
7/27/2017 | SP | New Issue: UBS prices $125,000 airbag yield optimization notes on AstraZeneca
|
6/26/2017 | SP | New Issue: UBS prices $1.06 million trigger phoenix autocallable optimization securities linked to AstraZeneca
|
6/5/2017 | EMHYPFPV | Market Commentary: AstraZeneca, Atmos Energy, ConEd, Dr Pepper Snapple tap primary market; credit spreads steady
|
6/5/2017 | IG | Market Commentary: AstraZeneca, Atmos Energy, ConEd, Dr Pepper Snapple tap primary market; credit spreads steady
|
6/5/2017 | IG | New Issue: AstraZeneca sells $2 billion three-part offering of fixed- and floating-rate notes
|
6/5/2017 | IG | Market Commentary: Morning Commentary: High-grade deal pipeline fills; AstraZeneca, Autodesk, Dr. Pepper to price
|
6/5/2017 | IG | AstraZeneca to sell three tranches of fixed-, floating-rate notes
|
5/19/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to AstraZeneca
|
5/9/2017 | SP | New Issue: UBS prices $343,000 trigger phoenix autocallables linked to AstraZeneca
|
5/5/2017 | SP | New Issue: UBS prices $544,000 trigger phoenix autocallables linked to AstraZeneca
|
5/5/2017 | SP | New Issue: UBS prices $708,500 trigger phoenix autocallables linked to AstraZeneca
|
5/1/2017 | SP | New Issue: Citigroup prices $4.68 million contingent income autocallables linked to AstraZeneca
|
4/19/2017 | IG | S&P revises AstraZeneca to negative
|
3/21/2017 | SP | New Issue: UBS prices $1.02 million trigger phoenix autocallables linked to AstraZeneca
|
12/27/2016 | SP | New Issue: UBS prices $425,000 trigger phoenix autocallables linked to AstraZeneca
|
12/21/2016 | SP | New Issue: UBS prices $230,000 trigger phoenix autocallables linked to AstraZeneca
|
12/19/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to AstraZeneca
|
12/16/2016 | SP | New Issue: UBS prices $1.01 million trigger phoenix autocallable optimization securities linked to AstraZeneca
|
12/15/2016 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to AstraZeneca
|
12/15/2016 | SP | New Issue: UBS prices $319,000 trigger phoenix autocallables linked to AstraZeneca
|
12/14/2016 | SP | New Issue: UBS prices $266,000 trigger phoenix autocallables linked to AstraZeneca
|
12/14/2016 | SP | New Issue: UBS prices $1.33 million trigger phoenix autocallables linked to AstraZeneca
|
12/14/2016 | SP | New Issue: UBS prices $280,000 trigger phoenix autocallables linked to AstraZeneca
|
10/7/2016 | SP | New Issue: RBC prices $6.47 million Accelerated Return Notes linked to pharma stocks
|
9/26/2016 | SP | RBC plans 14-month Accelerated Return Notes linked to pharma stocks
|
4/4/2016 | EMHYMUPFPV | Market Commentary: Primary sees $12 billion issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
|
4/4/2016 | IG | Market Commentary: Primary sees $12 billion of issuance from Target, BMW, others; Pfizer, AT&T tighten modestly
|
3/3/2016 | EMHYMUPFPV | Market Commentary: ConocoPhillips, Stryker price ahead of jobs data; AstraZeneca gains; Procter & Gamble eases
|
3/3/2016 | IG | Market Commentary: ConocoPhillips, Stryker price ahead of jobs data; AstraZeneca gains; Procter & Gamble eases
|
1/21/2016 | EMHYMUPFPV | Market Commentary: World Bank, Cades bring new issues; Shell tightens as oil prices rebound; Barclays firms
|
1/21/2016 | IG | Market Commentary: World Bank, Cades bring new issues; Shell bonds tighten as oil prices rebound; Barclays firms
|
1/12/2016 | EMHYMUPFPV | Market Commentary: Financials storm investment-grade primary; MetLife notes flat; Pfizer, AstraZeneca firm
|
1/12/2016 | IG | Market Commentary: Financials storm investment-grade primary; MetLife notes flat; Pfizer, AstraZeneca firm
|
12/18/2015 | IG | Moody’s downgrades AstraZeneca to A3
|
12/18/2015 | IG | S&P downgrades AstraZeneca to A-
|
12/18/2015 | IG | Fitch cuts AstraZeneca, debt to A
|
12/11/2015 | IG | Fitch changes AstraZeneca to negative
|
11/10/2015 | EMHYMUPFPV | Market Commentary: AstraZeneca does $6 billion deal; Canadian Railway, Burlington Northern trade mostly flat
|
11/10/2015 | IG | Market Commentary: AstraZeneca does $6 billion deal; Canadian Railway, Burlington Northern trade mostly flat
|
11/10/2015 | IG | New Issue: AstraZeneca prices $6 billion of notes in five tranches for ZS Pharma acquisition
|
11/10/2015 | IG | S&P downgrades AstraZeneca to A
|
11/10/2015 | IG | AstraZeneca sets talk for benchmark five-tranche offering of notes; pricing Tuesday
|
11/9/2015 | IG | Moody’s revises AstraZeneca to negative
|
5/1/2015 | IG | S&P drops AstraZeneca to A+
|
4/16/2015 | SP | New Issue: Barclays prices $1.38 million seven-year notes linked to basket of ADSs
|
11/21/2014 | IG | Fitch lowers AstraZeneca
|
8/29/2014 | SP | New Issue: Credit Suisse prices $550,000 contingent coupon autocallables linked to two stocks
|
8/19/2014 | SP | Credit Suisse plans contingent coupon autocallables tied to two stocks
|
7/31/2014 | SP | New Issue: Deutsche Bank prices $7.92 million trigger phoenix autocallables linked to AstraZeneca
|
7/23/2014 | SP | Deutsche Bank plans trigger phoenix autocallables tied to AstraZeneca
|
3/11/2014 | SP | New Issue: HSBC prices $7 million return enhanced notes linked to three stocks
|
3/5/2014 | SP | New Issue: HSBC prices $675,000 return enhanced notes linked to three stocks
|
2/27/2014 | SP | New Issue: HSBC prices $2.03 million return enhanced notes linked to three stocks
|
2/26/2014 | SP | HSBC plans three-year return enhanced notes linked to three stocks
|
2/24/2014 | SP | New Issue: HSBC prices $1.7 million return enhanced notes linked to pharma stocks
|
2/20/2014 | SP | New Issue: HSBC prices $1.1 million knock-out buffer notes linked to basket of three stocks
|
2/20/2014 | SP | New Issue: HSBC prices $2.69 million return enhanced notes linked to three stocks
|
2/20/2014 | SP | HSBC plans three-year return enhanced notes linked to three stocks
|
2/13/2014 | SP | HSBC to price knock-out buffer notes tied to basket of three stocks
|
2/11/2014 | SP | HSBC plans three-year return enhanced notes linked to three stocks
|
2/11/2014 | SP | New Issue: Deutsche Bank prices $445,000 return enhanced notes linked to pharma stocks
|
2/5/2014 | SP | New Issue: Deutsche Bank prices $4.23 million knock-out notes tied to three stocks
|
2/5/2014 | SP | New Issue: Deutsche Bank prices $1.26 million knock-out notes linked to three stocks
|
2/4/2014 | SP | New Issue: Deutsche Bank prices $3.42 million return enhanced notes linked to pharma stocks
|
1/29/2014 | SP | Deutsche Bank plans knock-out notes tied to basket of three stocks
|
11/22/2013 | IG | Fitch: AstraZeneca negative
|
4/11/2013 | IG | Moody's lowers AstraZeneca
|
4/8/2013 | IG | S&P cuts AstraZeneca view to negative
|
9/12/2012 | IG | Market Commentary: Midday Commentary: Market firms slightly, feels 'stalled' overall; AstraZeneca tightens
|
9/12/2012 | IG | New Issue: AstraZeneca gives terms of $2 billion sale of bonds due 2019, 2042
|
9/11/2012 | IG | AstraZeneca announces talk for note sale in seven-, 30-year tranches
|
9/11/2012 | IG | New Issue: AstraZeneca sells $2 billion of seven-, 30-year bonds
|
9/11/2012 | IG | Market Commentary: AstraZeneca returns to market with $2 billion deal, joins RBS, News America, Computer Sciences
|
7/5/2012 | IG | Moody's: AstraZeneca negative
|
10/11/2011 | IG | Fitch affirms AstraZeneca
|
12/21/2010 | IG | AstraZeneca files automatic shelf registration for debt securities
|
12/3/2010 | IG | Fitch affirms AstraZeneca
|
2/18/2009 | IG | Market Commentary: Roche sells mega deal, Canadian National Rail, Goodrich also price; DuPont new bonds widen
|
9/5/2008 | IG | Fitch affirms AstraZeneca
|
8/4/2008 | SS | Market Commentary: ImClone rejects $60 per share offer; Blackstone shops for theme parks; PeopleSupport jumps on Aegis buy
|
4/16/2008 | IG | Market Commentary: GE Capital prices massive deal on decent open, bank earnings; Martin Marietta also issues
|
9/13/2007 | IG | Market Commentary: Enel prices $3.5 billion of notes, Florida Power, J.P. Morgan also brave market on quiet day
|
9/6/2007 | IG | Market Commentary: Summer lull is over with more than $8 billion in new investment grade issues pricing
|
9/5/2007 | IG | New Issue: AstraZeneca prices $6.9 billion of notes in four tranches
|
9/5/2007 | IG | Market Commentary: Flood hits investment grade market with nearly $13 billion in new issues
|
9/4/2007 | IG | AstraZeneca to price notes in three tranches
|
8/31/2007 | IG | AstraZeneca files debt securities automatic shelf registration
|
6/11/2007 | SS | Market Commentary: Medivation spikes; H&R Block props up Jackson Hewitt, Intuit; Ford up; Affiliated Computer up
|
6/6/2007 | SS | AstraZeneca completes tender offer for MedImmune
|
4/23/2007 | SS | AstraZeneca to acquire MedImmune for $58 per share in all-cash transaction
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
3/8/2007 | SP | New Issue: ABN Amro prices $2.65 million 9% knock-in notes linked to Astrazeneca
|
3/5/2007 | SP | ABN Amro to price 9% reverse convertibles linked to Astrazeneca
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
9/21/2006 | BT | AstraZeneca to collaborate with ChemBridge on small molecule libraries
|
9/19/2006 | BT | Moody's affirms AstraZeneca
|
9/15/2006 | BT | Schering, AstraZeneca form alliance to develop breast cancer drug
|
9/14/2006 | BT | Array BioPharma gets $3 million milestone from AstraZeneca
|
9/6/2006 | BT | Dynavax, AstraZeneca to research use of TLR-9 agonists for asthma
|
8/7/2006 | BT | Immunicon, AstraZeneca enter research, master services agreements
|
8/2/2006 | BT | Pozen, AstraZeneca to develop combination pain reliever
|
8/1/2006 | BT | AstraZeneca: panel favors aromatase inhibitors over tamoxifen in early breast cancer treatment
|
7/25/2006 | BT | AstraZeneca: study shows Nexium better than Prevacid in preventing recurrence of erosive esophagitis
|
7/19/2006 | BT | Cambridge Antibody, Scil Proteins enter cross-license agreement
|
7/18/2006 | BT | AstraZeneca submits NDA for sustained-release formulation of Seroquel for schizophrenia
|
7/7/2006 | BT | Fitch affirms AstraZeneca
|
7/5/2006 | BT | Abbott, AstraZeneca to co-develop combination pill for lipid management
|
6/22/2006 | BT | AstraZeneca: Crestor lowers 'bad' cholesterol among various ethnicities
|
6/8/2006 | BT | AstraZeneca, Array begin phase 2 studies of melanoma treatment
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
6/7/2006 | BT | AstraZeneca's Zactima lung-cancer trials meet primary endpoint
|
6/6/2006 | BT | AstraZeneca: phase 2 studies of Zactima show progression free survival in lung cancer
|
5/23/2006 | BT | AstraZeneca says benefits of Seroquel in depression confirmed in second study
|
5/22/2006 | BT | AstraZeneca studies find Seroquel effective adjunct in depression treatment
|
5/16/2006 | BT | Epigenomics, AstraZeneca to continue oncology biomarker research
|
5/15/2006 | BT | AstraZeneca: Mercury II study shows Crestor improves cholesterol in high-risk patients
|
5/15/2006 | BT | AstraZeneca acquires Cambridge Antibody Technology for £702 million
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/1/2006 | BT | FDA approves use of Nexium in children ages 12 to 17 for short-term treatment of GERD
|
4/27/2006 | BT | Abraxis BioScience, AstraZeneca to co-promote Abraxane in the United States in $200 million deal
|
4/26/2006 | CV | New Issue: Barclays sells $1 million 8% reverse convertibles linked to AstraZeneca
|
4/5/2006 | CV | Barclays plans issue of 8% exchangeables linked to AstraZeneca
|
3/24/2006 | BT | AstraZeneca's Crestor study shows significant cholesterol reduction
|
3/22/2006 | BT | AstraZeneca's Nexium shown to reduce gastric ulcers in patients using long-term Nsaids
|
3/17/2006 | BT | AstraZeneca, University of Pennsylvania School of Medicine form research agreement
|
3/14/2006 | BT | AstraZeneca: Phase 2b trial shows NXY-059 well-tolerated in intracerebral hemorrhage patients
|
3/14/2006 | BT | AstraZeneca: Study shows Atacand cuts risk of hypertension by 15.6% for patients with prehypertension
|
3/13/2006 | BT | AstraZeneca reports data from two sub-studies for antiplatelet drug AZD6140
|
3/8/2006 | BT | AstraZeneca sues IVAX, alleging Nexium patent infringement
|
2/16/2006 | BT | AstraZeneca to appeal Toprol-XL patent decision
|
2/14/2006 | BT | AstraZeneca takes Exanta anticoagulant off market due to liver damage risk
|
2/8/2006 | BT | NPS, AstraZeneca research and development collaboration extended
|
2/3/2006 | BT | AstraZeneca upgraded to peer perform by Bear Stearns
|
2/2/2006 | BT | AstraZeneca's Zactima for thyroid cancer obtains FDA Fast Track designation
|
1/30/2006 | BT | AtheroGenics, AstraZeneca waiting period ends for license; AtheroGenics to get $50 million payment
|
1/18/2006 | BT | KV Pharmaceutical, Andrx win summary judgment in patent litigation with AstraZeneca
|
1/12/2006 | BT | AstraZeneca, M.D. Anderson Cancer Center to collaborate on cancer treatment research
|
1/3/2006 | BT | Avanir to receive $5 million milestone payment from AstraZeneca
|
12/30/2005 | BT | Targacept, AstraZeneca form research collaboration for Alzheimer's compound
|
12/30/2005 | BT | AstraZeneca submits supplemental NDA for Seroquel to treat depressive episodes of bipolar disorder
|
12/23/2005 | BT | AstraZeneca to acquire KuDOS Pharmaceuticals for $210 million
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/22/2005 | BT | AtheroGenics signs licensing deal with AstraZeneca for atherosclerosis drug worth up to $1 billion
|
12/14/2005 | BT | Fitch affirms AstraZeneca
|
12/8/2005 | BT | Protherics signs CytoFab deal with AstraZeneca worth potentially £195 million
|
11/16/2005 | BT | Astra-Zeneca says Zactima shrinks tumors for patients with rare thyroid cancer
|
11/1/2005 | BT | AstraZeneca files new drug application for combined Toprol-XL hypertension product
|
10/31/2005 | BT | IVAX said it intends to challenge AstraZeneca patents on Pulmicort Respules
|
10/31/2005 | BT | AstraZeneca's Zactima receives FDA orphan drug designation
|
10/21/2005 | BT | AstraZeneca: Study shows Seroquel effective for bipolar depression
|
10/6/2005 | BT | Jefferies raises Astra-Zeneca price target to $47.10
|
9/29/2005 | BT | AstraZeneca cut by Bear Stearns to peer perform
|
9/20/2005 | BT | AstraZeneca kept by Bear Stearns at outperform
|
7/13/2005 | BT | AstraZeneca initiated by Leerink Swann at outperform
|